11.80
-0.40 (-3.28%)
| Penutupan Terdahulu | 12.20 |
| Buka | 12.01 |
| Jumlah Dagangan | 783,904 |
| Purata Dagangan (3B) | 1,053,522 |
| Modal Pasaran | 1,189,982,848 |
| Harga / Jualan (P/S) | 10.32 |
| Harga / Buku (P/B) | 2.14 |
| Julat 52 Minggu |
| Margin Keuntungan | -82.68% |
| Margin Operasi (TTM) | 31.61% |
| EPS Cair (TTM) | -0.970 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.47% |
| Nisbah Semasa (MRQ) | 14.62 |
| Aliran Tunai Operasi (OCF TTM) | -89.48 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -151.71 M |
| Pulangan Atas Aset (ROA TTM) | -25.43% |
| Pulangan Atas Ekuiti (ROE TTM) | -17.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Day One Biopharmaceuticals, Inc | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.88 |
|
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 16.98% |
| % Dimiliki oleh Institusi | 93.03% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 30 Sep 2024 | 6,430,257 |
| Estuary Capital Management Lp | 30 Sep 2024 | 2,743,780 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (HC Wainwright & Co., 238.98%) | Beli |
| Median | 33.50 (183.90%) | |
| Rendah | 25.00 (B of A Securities, 111.86%) | Beli |
| Purata | 33.00 (179.66%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 12.89 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 13 Jan 2025 | 33.00 (179.66%) | Beli | 11.80 |
| 31 Oct 2024 | 33.00 (179.66%) | Beli | 14.72 | |
| B of A Securities | 07 Jan 2025 | 25.00 (111.86%) | Beli | 12.40 |
| Jones Trading | 17 Dec 2024 | 34.00 (188.14%) | Beli | 12.64 |
| HC Wainwright & Co. | 31 Oct 2024 | 40.00 (238.98%) | Beli | 14.72 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2025 | Pengumuman | Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities |
| 17 Dec 2024 | Pengumuman | Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 20 Nov 2024 | Pengumuman | Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development |
| 18 Nov 2024 | Pengumuman | Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference |
| 30 Oct 2024 | Pengumuman | Day One Reports Third Quarter 2024 Financial Results and Corporate Progress |
| 16 Oct 2024 | Pengumuman | Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |